Shield Tx Drug Patent Portfolio
Shield Tx owns 1 orange book drug protected by 3 US patents Given below is the list of Shield Tx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9802973 | Crystalline forms of ferric maltol | 23 Oct, 2035 | Active |
| US10179120 | Dosage regimen of ferric trimaltol | 06 Jan, 2035 | Active |
| US9248148 | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections | 29 Mar, 2031 | Active |
Latest Legal Activities on Shield Tx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Shield Tx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 22 Nov, 2023 | US9802973 |
|
Email Notification
Critical
| 22 Nov, 2023 | US10179120 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 22 Nov, 2023 | US10179120 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 22 Nov, 2023 | US9802973 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 06 Jul, 2022 | US10179120 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Apr, 2021 | US9802973 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 07 Apr, 2021 | US9802973 |
| Initial letter Re: PTE Application to regulating agency | 14 Jan, 2020 | US9802973 |
| Initial letter Re: PTE Application to regulating agency | 14 Jan, 2020 | US10179120 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Sep, 2019 | US9802973 |
|
Email Notification
Critical
| 25 Sep, 2019 | US10179120 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Sep, 2019 | US10179120 |
|
Email Notification
Critical
| 25 Sep, 2019 | US9802973 |
|
Correspondence Address Change
Critical
| 24 Sep, 2019 | US9802973 |
|
Correspondence Address Change
Critical
| 24 Sep, 2019 | US10179120 |
Shield Tx Drug Patents' Oppositions Filed in EPO
Shield Tx drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 05, 2018, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP15784705A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15784705A | Sep, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
Shield Tx's Family Patents
Shield Tx Drug List
Given below is the complete list of Shield Tx's drugs and the patents protecting them.
1. Accrufer
Accrufer is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9802973 | Crystalline forms of ferric maltol |
23 Oct, 2035
(10 years from now)
| Active |
| US10179120 | Dosage regimen of ferric trimaltol |
06 Jan, 2035
(9 years from now)
| Active |
| US9248148 | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
29 Mar, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Accrufer's drug page